Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension

European Respiratory Journal

Volumn 10, Issue 5, 1997, Pages 1084-1092

  Walmrath, D ^a   Schermuly, R ^a   Pilch, J ^a   Grimminger, F ^a   Seeger, W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

nitric oxide; prostacyclin; pulmonary hypertension; shunt flow; thromboxane analogue U 46619; ventilation perfusion ratio

Indexed keywords

EPOSTENOL; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E1; THROMBOXANE DERIVATIVE; U 44619; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAS EXCHANGE; IN VITRO STUDY; INHALATION; LUNG VENTILATION PERFUSION RATIO; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT; VASODILATATION;

EID: 0030958618     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10051084     Document Type: Article

References (40)

1. Fratacci MD, Frosteil CG, Chen TY, Wain JC Jr, Robinson DR, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75(6): 990-999.
2. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038-2047.
3. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancer 1991; 338: 1173-1174.
4. Rich GF, Murphy GD Jr, Roos CM, Johns RA. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993; 78(6): 1028-1035.
5. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-440.
6. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405.
7. Wysocki M, Delclaux C, Roupie E, et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bimesylate in the adult respiratory distress syndrome. Intensive Care Med 1994; 20: 254-259.
8. Puybasset L, Stewart T, Rouby JJ, et al. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology 1994; 80(6): 1254-1267.
9. 1 in the adult respiratory distress syndrome: benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 1989; 139: 106-116.
10. Radermacher P, Santak B, Wüst HT, Tarnow J, Falke KJ. Prostacyclin and right ventricular functions in patients with pulmonary hypertension associated with ARDS. Int Care Med 1990; 16: 227-232.
11. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet 1993; 342: 961-962.
12. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia: impact of fibrosis. Am J Respir Crit Care Med 1995; 151(3): 724-730.
13. Hardy CC, Bradding P, Robinson C, Holgate ST. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma. J Appl Physiol 1988; 64: 1567-1574.
14. Higgenbottam T. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Respir Dis 1987; 136: 782-785.
15. Zapol WM, Rimar S, Gillis N, Marietta M, Bosken CH. Nitric oxide and the lung. Am J Respir Crit Care Med 1994; 149(5): 1375-1380.
16. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with Superoxide. Am J Physiol 1995; 268: L699-L722.
17. 1 inhibits neutrophil adherence and neutrophil-mediated injury to cultured endothelial cells. Am Rev Respir Dis 1988; 138(4): 915-920.
18. Holtzman MT. Arachidonic acid metabolism: implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991; 143(1): 188-203.
19. Seeger W, Walmrath D, Menger M, Neuhof H. Increased lung vascular permeability after arachidonic acid and hydrostatic challenge. J Appl Physiol 1986; 61: 1781-1789.
20. Taylor AR, Gaar KA. Calculation of equivalent pore radii of the pulmonary capillary and alveolar membranes. Argent Angiol 1980; 111: 25-40.
21. Richardson PDI, Granger DN, Taylor AE. Capillary filtration coefficient: the technique and its application to the small intestine. Cardiovasc Res 1979; 13: 547-561.
22. Hakim TS, Kelly S. Occlusion pressures vs micropipette pressures in the pulmonary circulation. J Appl Physiol 1989; 67(3): 1277-1285.
23. Lindeborg DM, Kavanagh BP, Van Meurs K, Pearl RG. Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance. J Appl Physiol 1995; 78(1): 341-348.
24. Seeger W, Hansen T, Rössig R, et al. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability: effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvas Res 1995; 50: 1-17.
25. Schmehl T, Gebhardt J, Schütte H, Scharmann A, Seeger W. On-line laser-photometric monitoring of aerosol deposition in ventilated rabbit lungs. J Appl Physiol 1996; 80(1): 351-356.
26. Wagner PD, Saltzman HA, West JB. Measurement of continuous distributions of ventilation-perfusion ratios: theory. J Appl Physiol 1974; 36: 588-599.
27. Walmrath D, König R, Emst C, Brückner H, Grimininger F, Seeger W. Ventilation/perfusion relationships in isolated blood-free perfused rabbit lungs. J Appl Physiol 1992; 72: 374-382.
28. Walmrath D, Pilch J, Scharmann M, Grimminger F, Seeger W. Severe V'/Q' mismatch in perfused lungs evoked by sequential challenge with endotoxin and E. coli hemolysin. J Appl Physiol 1994; 76(3): 1020-1030.
29. Wagner PD, West JB. Ventilation-perfusion relationships. In: West JB, ed. Pulmonary Gas Exchange. New York, Academic Press, 1980; pp. 233-235.
30. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993; 88(6): 2884-2887.
31. Rimar S, Gillis CN. Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung. J Appl Physiol 1995; 78(5): 1745-1749.
32. Rimar S, Gillis CN. Pulmonary vasodilation by inhaled nitric oxide after endothelial injury. J Appl Physiol 1992; 73(5): 2179-2183.
33. Weibel ER. Morphological basis of alveolar-capillary gas exchange. Physiol Rev 1973; 53(2): 419-495.
34. Ralph DD, Robertson HT, Weaver LJ, Hlastala MP, Carrico CJ, Hudson LD. Distribution of ventilation and perfusion during positive end-expiratory pressure in the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 131: 54-60.
35. Lu Q, Mourgeon E, Law-Koune JD, et al. Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology 1995; 83(5): 929-943.
36. Gottschall EB, Fernyak S, Wuertemberger G, Voelkel AF. Almitrine mimics hypoxic vasoconstriction in isolated rat lungs. Am J Physiol 1992; 263: H383-H391.
37. Moncada S, Vane JR. Prostacyclin in the cardiovascular system. In: Samuelson B, Ramwell PW, Paoletti R, eds. Advances in Prostaglandin and Thromboxane Research. New York, Raven Press, 1980; pp. 43-59.
38. 1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137(1): 5-12.
39. 1 in man. Eicosanoids 1991; 4(3): 177-184.
40. 1 in patients with peripheral arterial occlusive disease. Prostaglandins 1991; 41(3): 225-228.